Heart News and Research

RSS

Susquehanna Health acquires a Daxor blood volume analyzer

Daxor Corporation, a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from Susquehanna Health of Williamsport, Pennsylvania. This will provide Susquehanna Health with a Blood Volume Analyzer-100 (BVA-100), an instrument which enables semi-automated measurement of a patient's total blood volume, red blood cell volume and plasma volume.

8 Oct 2009

New study to assess the risk of heart disease in diabetics

In a new international partnership, Dr. Randy Nelson, a researcher at Arizona State University's Biodesign Institute, and Dr. Tai E-Shyong , associate professor at Singapore's National University Hospital, National University Health System (NUHS), have teamed up to assess the risk of heart disease in diabetics with greater accuracy.

8 Oct 2009

Pfizer-FRSQ Innovation Fund supports genetic study of inflammatory bowel disease and cancer

The first two research projects supported by the Pfizer-FRSQ Innovation Fund will investigate differences in the genetic code for inflammatory bowel disease and metastatic colorectal cancer. This research could lead to improved diagnosis and the development of individualized treatments for these diseases. These innovative projects are marshalling multidisciplinary teams of seasoned researchers from major Quebec research institutions.

8 Oct 2009

NHLBI awards $11 million to research on the biology of two fatal lung diseases

Researchers at National Jewish Health and four other research centers have been awarded an $11 million, two-year grant from the National Heart Lung and Blood Institute as part of the NIH Recovery Act that will allow a team of national scientists to delve deeply into the biology of two fatal lung diseases for which there are few therapeutic options.

8 Oct 2009

Hoana Medical to be showcased at the FiReGlobal : West Coast conference

FiReGlobal : West Coast is proud to announce that Hoana Medical, Inc. has been selected as a FiReStar company to be featured at the FiReGlobal : West Coast conference. FiReStar companies, both local and global, are pre-selected based on their potential to bring positive change to the world. These companies will be showcased throughout the conference, and at a FiReStar reception, during which local and global investors will be given the chance to meet company officers.

8 Oct 2009

White House honors PET researcher with National Science Award

Joanna Fowler, Ph.D., a major contributor to brain research and a pioneer in molecular imaging, is being recognized by the White House with the National Medal of Science-the highest award for lifetime achievement in science. Eight other researchers will join Fowler to receive the award at a White House ceremony on October 7.

8 Oct 2009

Antioxidants can contribute to early onset of Type 2 diabetes

An international team of scientists, led by Monash University researchers, has found that anti-oxidants commonly touted for their health-promoting benefits, could contribute to the early onset of Type 2 diabetes.

8 Oct 2009

NIH funds Triple Ring Technologies' X-ray imaging system development

Triple Ring Technologies, Inc., a leading provider of early-stage advanced research and development services, today announced that it has been awarded a Challenge Grant from the National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), as part of the American Recovery and Reinvestment Act (ARRA).

8 Oct 2009

Relypsa commences patient enrollment in Phase 2b clinical trial of RLY5016 for treating hyperkalemia

Relypsa, Inc., today announced the initiation of patient enrollment in the PEARL-HF study, a Phase 2b clinical trial of the company’s lead compound, RLY5016. A novel potassium binder designed for chronic use, RLY5016 is being evaluated in the prevention and treatment of hyperkalemia, for which there are no current satisfactory treatments.

7 Oct 2009

Arizona Heart Institute partners with Arizona Research Center for the advancement of cardiovascular therapies

Arizona Heart Institute, a world leading medical facility specializing in diagnosis, treatment and prevention of heart and vascular disease, and Arizona Research Center, a dedicated provider of clinical research studies, announce a partnership in the advancement of cardiovascular therapies.

7 Oct 2009

New report on the relationship between secondhand smoke and heart disease

The dangers of secondhand smoke have led some organizations and communities to establish smoking bans in offices, restaurants, and other public venues. The effectiveness of such bans in protecting people from health risks associated with breathing environmental tobacco smoke has been a matter of continuing debate.

7 Oct 2009

The Top 10 Medical Innovations for 2010 announced at Cleveland Clinic Medical Innovation Summit

Cleveland Clinic's Top 10 Medical Innovations for 2010 list features a wide range of new techniques and therapies that are being developed to treat everything from deafness and Parkinson's disease to pneumonia and sleep disorders.

7 Oct 2009

HSCI declares preliminary price range for its initial public offering

Joint Stock Company Human Stem Cell Institute” (“HSCI” or “the Company”), Russia’s leader in stem cell technology, today announced the preliminary price range for its initial public offering (“IPO”).

7 Oct 2009

Presbyterian Hospital implements Defensive Monitoring solution for their post-surgical patients

Presbyterian Hospital will “go live” today with a Defensive Monitoring™ solution for their post-surgical patients: A Prefense™ Early Detection and Notification™ System from Nihon Kohden America, Inc.

7 Oct 2009

Research to explore diagnosis and treatment of rare diseases

The National Institutes of Health announced today a second phase of the Rare Diseases Clinical Research Network (RDCRN) including funds for 19 research consortia.

7 Oct 2009

Award-winning GWTG hospitals have lower mortality rates for heart attack and heart failure patients: Study

Hospitals receiving performance awards from the American Heart Association's Get With The Guidelines (GWTG) quality improvement initiative have lower mortality rates for heart attack and heart failure patients than all other hospitals, according to a new study.

7 Oct 2009

Findings from a study of Vicor's PD2i VS to be presented at the Resuscitation Science Symposium 2009

David H. Fater, CEO of Vicor Technologies, Inc., today announced that Andriy Batchinsky, MD, a researcher with the U.S. Army Institute of Surgical Research (USAISR), will present findings from a study of Vicor's PD2i VS™ (Vital Sign) at the American Heart Association's Resuscitation Science Symposium 2009 on November 14-15, 2009 in Orlando, Florida.

7 Oct 2009